Sondalo

Researchers are investigating the evolution of neoadjuvant treatment for early breast cancer, focusing on patients with HER2-positive and Triple Negative tumors. The study aims to determine the percentage of these patients who received neoadjuvant therapy over the past five years, regardless of molecular subtype. Secondary goals include analyzing treatment choices, tumor characteristics, radiological responses, surgical procedures, adjuvant therapies, eligibility criteria changes, pathological complete response, disease-free survival, and overall survival according to molecular subtype and initial staging. This retrospective multicenter study reviews clinical practices in Italian oncology centers from 2016 to 2021. It includes patients diagnosed with early-stage breast cancer (stages I-III) who underwent neoadjuvant treatment. The study collects data on tumor subtype, treatment regimens, imaging methods such as breast MRI, ultrasound, mammography, and surgical treatments to understand therapeutic approaches and outcomes. Participants undergo data collection from medical records regarding tumor pathology, treatment responses, and survival outcomes over five years. Researchers measure the percentage of HER2-positive and Triple Negative tumors treated neoadjuvantly and perform descriptive analyses on treatment patterns and clinical features. The study also evaluates disease-free and overall survival related to pathological response and tumor subtype, providing insights into real-world treatment effectiveness and outcomes in early breast cancer.